Percutaneous ethanol injection in the treatment of hepatocellular carcinoma - A multicenter survey of evaluation practices and complication rates

被引:18
作者
DiStasi, M
Buscarini, L
Livraghi, T
Giorgio, A
Salmi, A
DeSio, I
Brunello, F
Solmi, L
Caturelli, E
Magnolfi, F
Caremani, M
Filice, C
机构
[1] HOSP VIMERCATE, DEPT RADIOL, VIMERCATE, ITALY
[2] SANTORSOLA HOSP, COTUGNO HOSP INFECT DIS, DIV MED, BRESCIA, ITALY
[3] UNIV NAPLES 2, DEPT GASTROENTEROL, NAPLES, ITALY
[4] HOSP ORBASSANO, DEPT INTERNAL MED, ORBASSANO, ITALY
[5] SANTORSOLA MALPIGHI HOSP, GASTROENTEROL UNIT, BOLOGNA, ITALY
[6] SOFFERENZA HOSP, CASA SOLLIEVO, DIV GASTROENTEROL, SAN GIOVANNI ROTONDO, ITALY
[7] HOSP AREZZO, GASTROENTEROL UNIT, AREZZO, ITALY
[8] HOSP AREZZO, INFECT DIS UNIT, AREZZO, ITALY
[9] UNIV PAVIA, SAN MATTEO HOSP, INFECT DIS CLIN, I-27100 PAVIA, ITALY
关键词
alcohol; interventional procedures; complications; liver; liver neoplasms; therapy;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Percutaneous ethanol injection (PEI) has become a widely used procedure in the treatment of hepatocellular carcinoma (HCC). However, the criteria for selecting patients are not standardized, and little information is available about the complications of the procedure. Methods: A questionnaire was sent to 11 experienced Italian centers. It investigated: the size and the number of HCC nodules suitable for treatment and the Child-Pugh risk class of the associated cirrhosis; the performance of the procedure; the number and characteristics of the patients treated; and, finally, any complications. Results: Most of the centers performed PEI in single HCC nodules less than 5 cm in diameter or in multiple nodules if fewer than three, the larger being less than 3 cm. Patients in Child-Pugh's classes A, B, and C with single nodules were generally considered for PEI. A prothrombin time of less than 40% and a platelet count of less than 40,000/mm(3) contraindicated PEI in most of the centers. PEI was generally performed on outpatients, using Chiba or spinal needles. One thousand and sixty-six patients (8118 sessions) were enrolled; 74% had a single HCC nodule and 26% multiple nodules. All except four had cirrhosis; 53% were in Child class A, 38% in class B, and 9% in class C. The mean number of sessions needed to destroy an HCC nodule was 6.7 (range, 2-14), with a mean alcohol injection volume of 5.0 ml per session (range, 2-20 ml). One death (0.09%) and 34 complications (3.2%) were reported. Among the complications we call attention to the hemorrhagic ones (eight cases) and tumoral seeding (seven cases). Severe pain experienced during the maneuver led to discontinuation of the procedure in 3.7% of the patients; 13.5% of the patients required analgesics and 24% had fever after PEI. Conclusions: Some procedural aspects of PEI treatment differ among the various centers: a standardization is advisable. In the present survey PEI is a low-risk technique.
引用
收藏
页码:1168 / 1173
页数:6
相关论文
共 34 条
[1]
NEOPLASTIC SEEDING COMPLICATING PERCUTANEOUS ETHANOL INJECTION FOR TREATMENT OF HEPATOCELLULAR-CARCINOMA [J].
CEDRONE, A ;
RAPACCINI, GL ;
POMPILI, M ;
GRATTAGLIANO, A ;
ALIOTTA, A ;
TROMBINO, C .
RADIOLOGY, 1992, 183 (03) :787-788
[2]
Di Stasi M, 1996, J INTERVENT RADIOL, V11, P43
[3]
PERCUTANEOUS ETHANOL INJECTION FOR THE TREATMENT OF SMALL HEPATOCELLULAR-CARCINOMA - STUDY OF 95 PATIENTS [J].
EBARA, M ;
OHTO, M ;
SUGIURA, N ;
KITA, K ;
YOSHIKAWA, M ;
OKUDA, K ;
KONDO, F ;
KONDO, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1990, 5 (06) :616-626
[4]
GIORGIO A, 1992, J ULTRAS MED, V11, P587
[5]
ISOBE H, 1990, AM J GASTROENTEROL, V85, P1646
[6]
KAWANO M, 1989, Gastroenterologia Japonica, V24, P663
[7]
HEPATIC VASCULAR AND BILE-DUCT INJURY AFTER ETHANOL INJECTION THERAPY FOR HEPATOCELLULAR-CARCINOMA [J].
KODA, M ;
OKAMOTO, K ;
MIYOSHI, Y ;
KAWASAKI, H .
GASTROINTESTINAL RADIOLOGY, 1992, 17 (02) :167-169
[8]
LENCIONI R, 1995, CANCER, V76, P1737, DOI 10.1002/1097-0142(19951115)76:10<1737::AID-CNCR2820761010>3.0.CO
[9]
2-P
[10]
LIVRAGHI T, 1992, CANCER, V69, P925, DOI 10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO